Bioavailability of BIBR 1048 MS Single Doses With or Without Pantoprazole in Healthy Subjects
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The pharmacokinetics of 50 mg BIBR 1048 administered as two newly developed capsule
formulation using melt extrusion technology was assessed in two separate, single dose, 3-way
crossover, open design, randomised studies. The 3-way crossover treatments included
administration of the tartaric acid solution of 50 mg BIBR 1048, the capsule formulation A or
B and administration of the capsules with coadministration of pantoprazole.